← SynDRA
MACITENTAN
SynDRA canonical compound SYN0030071 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | EDNRB |
|---|
| Mechanism of action | Endothelin receptor antagonist |
|---|
| Indication | contraceptive |
|---|
| Disease area | endocrinology |
|---|
All known targets
Mechanisms of action (all sources)
- Endothelin receptor antagonist
- EDNRB ANTAGONIST
- Endothelin receptor, ET-A/ET-B antagonist
- EDNRA ANTAGONIST
- EDNRA MODULATOR
- EDNRB MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- TSPO
- SLC6A4
- SLC6A2
- DRD3
- NEIL2
- HTR1D
- HTR1E
- HTR2A
- HTR2C
- HTR6
- MBD4
- MPG
- MUTYH
- NEIL1
- OGG1
- NTHL1
- HTR1A
- OPRD1
- OPRK1
- OPRM1
- S1PR1
- SIGMAR1
- SLC6A3
- SMUG1
- TDG
- TMEM97
- HTR1B
- ADGRF1
- ADRA1B
- CHRM4
- ADRA1D
- ADRA2A
- ADRA2C
- ADRB2
- ADRB3
- AGTR1
- APLNR
- C5AR1
- CHRM2
- CHRM3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Endothelin Receptor Antagonists
- Endothelin Receptor Antagonist
- Endothelin A Receptor Antagonists
- Endothelin B Receptor Antagonists
ATC classes
- C02K · OTHER ANTIHYPERTENSIVES
Cross-references
Synonyms
- OPSUMIT
- OPSYNVI
- Opsumit
- opsumit
- ACT-064992
- Macitentan component of opsynvi
- ACT 064992
- UNII-Z9K9Y9WMVL
- ACT064992
- Z9K9Y9WMVL
- CHEBI:76607
- Actelion-1
- Macitentan [USAN:INN]
- macitentanum
- zlchem 5
- Opsumit (TN)
- Macitentan (JAN/USAN)
- (non-labelled)Macitentan-d7
- MLS006011174
- C19H20Br2N6O4S
- SCHEMBL1445625
- GTPL7352
- CHEMBL2103873
- ZLA0005
- EX-A544
- DTXSID50196063
- OPSYNVI COMPONENT MACITENTAN
- RefChem:58979
- C02KX04
- DTXCID60118554
- MFCD17167076
- Macitentan [INN]
- Macitentan (Standard)
- MACITENTAN [MI]
- MACITENTAN [JAN]
- MACITENTAN [USAN]
- MACITENTAN [VANDF]
Reported adverse events
- Bronchitis
- Headache
- Influenza
- Nasopharyngitis
- Urinary tract infection
- Hepatotoxicity
Look up MACITENTAN in the interactive SynDRA portal →